Cogent Biosciences (COGT) – PRNewswire
-
Cogent Biosciences Provides 2022 Corporate Guidance
-
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results
-
Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021
-
Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetration
-
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference
-
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
-
Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021
-
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021
-
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
-
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
-
Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer
-
Cogent Biosciences Announces Creation of Cogent Research Team
-
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
-
Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors
-
Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021
-
Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021
-
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
-
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
-
Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock
-
Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer
-
Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference
-
Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020
-
Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference
-
Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
-
Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer
Back to COGT Stock Lookup
